Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis

Li, Jinghu; Liu, Qingjing; Chen, Yi; Gao, Shuangqing; Zhang, Jie; Yang, Yicheng; Chen, Wendong

doi:10.1080/13696998.2016.1227829

Cited by 9 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between patient demographics, baseline comorbidities of interest, baseline medications received, and the subsequent initiation of a bDMARD in the 12 months after diagnosis of AS was assessed using a multivariable logistic regression model. The selection of covariates was based on clinical importance and a literature review [16,17].…”

Section: Discussionmentioning

confidence: 99%

Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis

Tomita

Sato

Esterberg

et al. 2020

Modern Rheumatology

View full text Add to dashboard Cite

Objectives: To understand the current state of treatment patterns and health care resource utilization among patients in Japan with ankylosing spondylitis (AS) managed in the real-world setting. Methods: Patient records from the Medical Data Vision database were analyzed to identify patients with ICD-10 AS from April 2009 through July 2017. Measures evaluated included demographic, clinical, and other characteristics at diagnosis; treatment patterns; health care resource utilization; and costs. Results: Four hundred and seventeen patients met the study's inclusion criteria. Treatments observed during the first year after the initial AS diagnosis included nonsteroidal anti-inflammatory drugs (79.6%), corticosteroids (39.3%), methotrexate (22.3%), sulfasalazine (16.8%), adalimumab (14.2%), and infliximab (12.2%). At any time during the mean 33 months of study follow-up, biologic disease-modifying antirheumatic drugs (bDMARDs) were initiated by 115 patients. During the study follow-up, patients who initiated bDMARDs had higher median total per-patient annual health care costs

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis

Tomita

Sato

Esterberg

et al. 2020

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…For AxSpA, NSAIDs are often the first-line treatment, and biologics are the step-up treatment for patients who have inadequate response to NSAIDs [27]. However, the cost difference between NSAIDs and biologics is very large [51]. Patients who have inadequate response to NSAIDs but cannot afford biologics often experience significant pain and impairment in QoL [52].…”

Section: Discussionmentioning

confidence: 99%

Traditional Chinese medicine (TCM) collaborative care for patients with axial spondyloarthritis (AcuSpA): protocol for a pragmatic randomized controlled trial

Kwan

Fong

Ang³

et al. 2019

Trials

View full text Add to dashboard Cite

BackgroundAxial spondyloarthritis (AxSpA) is a chronic disease which results in fatigue, pain, and reduced quality of life (QoL). Traditional Chinese medicine (TCM), especially acupuncture, has shown promise in managing pain. Although a TCM collaborative model of care (TCMCMC) has been studied in cancer, there are no randomized controlled trials investigating TCM in AxSpA. Therefore, we will conduct a pragmatic trial to determine the clinical effectiveness, safety, and cost-effectiveness of TCMCMC for patients with AxSpA. We define TCMCMC as standard TCM history taking and physical examination, acupuncture, and TCM non-pharmacological advice and communications with rheumatologists in addition to usual rheumatologic care. The purpose of this paper is to describe the rationale for and methodology of this trial.Methods/designThis pragmatic randomized controlled trial will recruit 160 patients who are diagnosed with AxSpA and have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs). Simple randomization to usual rheumatologic care or the intervention (TCMCMC) with a 1:1 allocation ratio will be used. Ten 30-min acupuncture sessions will be provided to patients assigned to the TCMCMC arm. All participants will continue to receive usual rheumatologic care. The primary endpoint — spinal pain — will be evaluated at week 6. Secondary endpoints include clinical, quality of life, and economic outcome measures. Patients will be followed up for up to 52 weeks, and adverse events will be documented.DiscussionThis trial may provide evidence regarding the clinical effectiveness, safety, and cost-effectiveness of a TCMCMC for patients with AxSpA.Trial registrationClinicalTrials.gov, NCT03420404. Registered on 14 February 2018.Electronic supplementary materialThe online version of this article (10.1186/s13063-018-3117-2) contains supplementary material, which is available to authorized users.

show abstract

“…Previous retrospective studies have predominantly focused on treatment patterns and costs of TNFis. 31,32 Therefore, there is a need for more studies evaluating the real-world health care costs and utilization associated with newer biologic treatments for RESULTS: A total of 791 patients with AS who were newly initiating a biologic were categorized as switchers (15.4%), nonswitchers (53.1%), and discontinuers (31.5%). Switchers and discontinuers had higher all-cause health care utilization than nonswitchers during the 1-year follow-up period.…”

Section: What This Study Addsmentioning

confidence: 99%

“…A previous study using a claims database in China reported that patients with AS receiving biologics have the highest direct medical costs compared with those on other conventional therapies. 32 To account for potential confounding of baseline health status, we adjusted for baseline covariates that may represent a patient's need for health care services as a proxy for health status or predictors of future health care utilization (e.g., age, sex, and comorbidities).…”

Section: Limitationsmentioning

confidence: 99%

Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis

Dai

Piao

et al. 2021

JMCP

View full text Add to dashboard Cite

BACKGROUND: Costs associated with biologic switching and discontinuation can be high in chronic inflammatory diseases. Inappropriate use of medications may have cost implications for both payers and patients. Understanding of biologic utilization and switching rates is lacking among patients with ankylosing spondylitis (AS). OBJECTIVE:To compare direct costs of treatment switchers, nonswitchers, and discontinuers among patients with AS who newly initiated a biologic.

show abstract

Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis

Abstract: Biologics were not commonly used for AS in Chinese patients likely due to their high cost. Future studies are needed to confirm the potential long-term clinical benefits associated biologic treatment for AS.

Cited by 9 publications

References 12 publications

Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis

Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis

Traditional Chinese medicine (TCM) collaborative care for patients with axial spondyloarthritis (AcuSpA): protocol for a pragmatic randomized controlled trial

Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis

Contact Info

Product

Resources

About